Literature DB >> 10591687

In vivo regulation of von willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs.

J P Brouland1, T Egan, J Roussi, M Bonneau, G Pignaud, C Bal, M Vaiman, P André, P Hervé, G M Mazmanian, L Drouet.   

Abstract

To evaluate the regulation of plasma von Willebrand factor (vWF) and its in situ production by endothelial cells (ECs), 12 swine leukocyte antigen (SLA)-compatible left lung transplantations were performed. Normal lungs were transplanted into 10 pigs homozygous for von Willebrand disease and into 2 normal pigs. Additionally, 1 normal pig underwent pneumonectomy, and 1 SLA-incompatible lung transplantation between normal pigs was performed. None of the transplanted animals received immunosuppressive therapy. Plasma vWF level was evaluated by ELISA and multimeric pattern. EC vWF content was assessed by immunohistochemistry. Global hemostasis was assessed by standardized ear bleeding time. Six of 12 SLA-compatible lung transplantations and the incompatible transplantation were successful and were used for the study. The functions and the viability of ECs, reflected by their ability to produce vWF and normal multimeric plasma vWF pattern, were preserved in SLA-compatible and -incompatible lung transplantations. vWF production was preserved in ECs that initially synthesized it. EC constitutive and storage pathways are modulated differently according to transplantation compatibility and severity of rejection. In SLA-compatible lung transplantations without histological evidence of rejection, the production of vWF was preserved, whereas constitutive vWF secretion appeared to be altered in cases with minor histological signs of rejection. In pigs with von Willebrand disease that were transplanted with normal lungs without sign of rejection, plasma vWF was significantly increased in an amount expected from the estimated production of a normal lung. In the transplanted normal lung, there was no vWF overexpression by the ECs and no recruitment of ECs that initially did not express vWF. In SLA-incompatible transplantation, ECs were morphologically normal with increased and blurred vWF labeling, whereas plasma vWF levels remained normal, reflecting that EC activation is associated with an increased vWF production with probable diversion to storage pathway. This model depicts the changes of EC regulation of vWF secretion in pig lung transplants. However, this model cannot be directly extrapolated to human organ transplantation because animals did not receive any immunosuppressive therapy, which may be toxic to ECs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591687     DOI: 10.1161/01.atv.19.12.3055

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

1.  Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia.

Authors:  Margaret V Ragni; Rachel C Jankowitz; Kristen Jaworski; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2011-08-11       Impact factor: 5.249

Review 2.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

3.  Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort.

Authors:  Marco Campos; Wei Sun; Fuli Yu; Maja Barbalic; Weihong Tang; Lloyd E Chambless; Kenneth K Wu; Christie Ballantyne; Aaron R Folsom; Eric Boerwinkle; Jing-Fei Dong
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

Review 4.  Traumatic brain injury-associated coagulopathy.

Authors:  Jianning Zhang; Rongcai Jiang; Li Liu; Timothy Watkins; Fangyi Zhang; Jing-fei Dong
Journal:  J Neurotrauma       Date:  2012-10-31       Impact factor: 5.269

5.  Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.

Authors:  Margaret V Ragni; Enrico M Novelli; Anila Murshed; Elizabeth P Merricks; Mark T Kloos; Timothy C Nichols
Journal:  Thromb Haemost       Date:  2012-12-13       Impact factor: 5.249

Review 6.  Coagulopathy associated with traumatic brain injury.

Authors:  Monisha A Kumar
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

7.  A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease.

Authors:  M V Ragni; R C Jankowitz; H L Chapman; E P Merricks; M T Kloos; A M Dillow; T C Nichols
Journal:  Haemophilia       Date:  2008-08-01       Impact factor: 4.287

8.  Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions.

Authors:  Y Li; H Choi; Z Zhou; L Nolasco; H J Pownall; J Voorberg; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

Review 9.  Acquired von Willebrand syndrome associated with left ventricular assist device.

Authors:  Angelo Nascimbene; Sriram Neelamegham; O H Frazier; Joel L Moake; Jing-Fei Dong
Journal:  Blood       Date:  2016-05-03       Impact factor: 22.113

Review 10.  Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic.

Authors:  David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.